The multikinase-inhibition action of sorafenib provides strong rationales for its combination
use with radiotherapy. We investigated the in vitro and in vivo effect of sorafenib combined …

Purpose: Sorafenib, an oral multikinase inhibitor, is the first agent that has demonstrated an
improved overall survival benefit in advanced hepatocellular carcinoma, setting a new …

Background Hepatocellular carcinoma (HCC) has a high incidence and mortality.
Radiotherapy and sorafenib have proven effective for HCC. Here, we investigated whether …

Sorafenib, an orally available multikinase inhibitor, combined with radiation has shown
potential as an anticancer treatment in an in vitro and in vivo colon cancer model. In this …

The antineoplastic drug sorafenib (BAY 43-9006) is a multikinase inhibitor that targets the
serine-threonine kinase B-Raf as well as several tyrosine kinases. Given the numerous …

High expression of vascular endothelial growth factor (VEGF) in patients with breast cancer
has been associated with a poor prognosis, indicating that VEGF could be linked to the …

OBJECTIVE: Sorafenib is an oral multikinase inhibitor that has been proven effective as a
single-agent therapy in hepatocellular carcinoma, and there is a strong rationale for …

Patients with unresectable hepatocellular carcinoma (HCC) usually have poor prognosis
because current monotherapy including surgery, chemotherapy and radiotherapy (RT) are …

Over-expression of transcription factor nuclear factor-κB (NF-κB) in the residual tumor after
the treatment is often observed at the later period of cancer radiotherapy, results in tumor …

Conformal radiotherapy is a promising therapeutic strategy for hepatocellular carcinoma
(HCC), producing local control rates above 90% within the radiation beam. However …